Asthma Clinical Trial
Official title:
Effects of Aerobic Training Versus Behavioral Intervention to Increase Physical Activity in Patients With Asthma: a Randomized, Blinded Clinical Trial.
To compare the effects of aerobic training and behavioural intervention to increase physical activity in the clinical control of asthma and in the quality of life of patients with asthma.
Status | Recruiting |
Enrollment | 56 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Participants not physically active; 2. Uncontrolled asthma (ACQ>1,5); 3. Diagnosis of asthma based on the recommendations of the Global Initiative for Asthma (GINA 2020); 4. Be under outpatient follow-up at the Pulmonology or Immunology service of the University of Sao Paulo General Hospital; 5. Be under outpatient medical treatment for at least six months, with a stable clinical condition for at least 30 days; 6. Being using optimized drug therapy for asthma. Exclusion Criteria: 1. Participation in another research protocol; 2. Difficulty in understanding any of the questionnaires used; 3. Practitioners of regular physical activity; 4. Pregnancy and psychiatric problems that make it difficult to understand the questionnaires and the study protocol; 5. Presence of another chronic lung, neurological or musculoskeletal disease that hinders or prevents physical activity; 6. Patients who are smokers or ex-smokers (who have quit smoking for less than 1 year or who have smoked more than 15 pack-years). |
Country | Name | City | State |
---|---|---|---|
Brazil | Clinical Hospital of São Paulo University medical school (HCFMUSP) | São Paulo |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo General Hospital | Fundação de Amparo à Pesquisa do Estado de São Paulo |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in Barriers to the practice of Physical Activities of Daily Living | The possible answers to the questionnaire Barriers to the practice of Physical Activities of Daily Living are never, rarely, sometimes, almost always or always and the score for each item varies from 0 to 4. It will be considered as limiting domain for physical activities those in which individuals report a value equal to or greater than 3 in at least half of the barriers. | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention] | |
Other | Change in asthma exacerbation | Asthma exacerbation will be assessed by the following criteria: the use of =4 puffs of rescue medication per 24 hours during a 48-hour period, a need for systemic corticosteroids, an unscheduled medical appointment, and either a visit to an emergency room or hospitalization | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Other | Change in Behavioral Stage for physical activity practice | The Behavioral Stage Assessment Questionnaire for the Practice of Physical Activity qualitatively assesses thinking in relation to the practice of physical activity, and may present the following stages of behavior: 1. Pre-contemplation; 2. Contemplation; 3. Preparation; 4. Action; 5- Maintenance. |
Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Other | Pulmonary function | Lung volumes will be assessed by spirometry | Baseline | |
Other | Change in anthropometric indexes | Waist circumference (cm) and hip circumference (cm) will be combined to report wait to hip ratio (WHR). | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Other | Sleep quality assessment | The assessment of sleep quality will be performed by the accelerometer (Actigraph, GT9) for seven nights before and after the interventions, throughout the day. The outcomes derived from the monitor will be sleep latency (the amount of time needed to fall asleep) and sleep efficiency (number of sleep minutes divided by the total number of minutes the participant was in bed). | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Other | Cardiopulmonary Exercise Test | CPET will be performed on an electric cycle ergometer (Corival; Lode BV Medical Technology, Netherlands) equipped with an electronic system (CPX System; CareFusion, Germany). During the test there will be verbal encouragement for the patient to reach maximum effort. The maximum oxygen consumption (VO2 peak in ml.kg.min) will be evaluated, considered the highest value in the test phase; anaerobic threshold (will be determined from the exponential growth of ventilation, additionally by the increase in VCO2, fall and/or stabilization of VO2, also considering the VCO2/VO2 ratio close to 1; respiratory compensation point (will be determined from the second point inflection, exponential growth in ventilation, additionally due to the increase in VCO2 and exponential fall in VO2, also considering the VCO2/VO2 ratio greater than or equal to 1.10; maximum heart rate (established by electrocardiogram examinatio). | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Primary | Change in asthma clinical control | Clinical control will be evaluated by the Asthma Control Questionnaire (ACQ). The ACQ contains 7 items rated on a 7- point scale (0 = without limitation, 6 = maximum limitation), with a higher score indicating worse control. Scores lower than 0.75 are associated with good asthma control, whereas scores greater than 1.5 are indicative of poorly controlled asthma, and a change of at least 0.5 points in the ACQ score is regarded as clinically significant. | [Change from baseline at 8 weeks of intervention and at 16 weeks post intervention] | |
Secondary | Change in sedentary behaviour | Sedentary behaviour will be objectively quantified using a movement sensor (ActiGraph, Pensacola, USA) for 7 consecutive days on the hip using an elastic belt. Sedentary behaviour will be quantify by the time spent sedentary (<100 counts/min). | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Secondary | Change in physical activity levels | Physical activity will be objectively quantified using a movement sensor (ActiGraph, Pensacola, USA) for 7 consecutive days on the hip using an elastic belt. | [Time Frame: Change from baseline at 8 weeks of intervention and at 16 weeks post intervention] | |
Secondary | Change in Health Factors Related to Quality of Life in Asthma | Health related quality of life will be assessed by Asthma Quality Life Questionnaire (AQLQ). The AQLQ consists of 32 items rated on a 7-point scale (1 = great deal, 7 = not at all) divided into the following 4 domains: activity limitations, symptoms, emotional function and environmental stimuli. Higher AQLQ scores indicate a better quality of life, and treatments resulting in a 0.5-point increase in scores following an intervention are considered to be clinically effective. | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Secondary | Change in psychosocial symptoms | Symptoms of anxiety and depression symptoms will be assessed by the Hospital Anxiety and Depression scale (HADs), which consists of 14 items divided into 2 subscales (7 for anxiety and 7 for depression). Each item is scored from 0 to 3, with a maximum score of 21 points for each subscale. A score greater than 8/9 in each subscale suggests a diagnosis of either anxiety and/or depression. | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Secondary | Change in body composition - Weight | Bioimpedance (Octopolar InBody 720). | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Secondary | Change in body composition - Fat mass | Bioimpedance (Octopolar InBody 720). | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention | |
Secondary | Change in body composition - Visceral adiposity area | Bioimpedance (Octopolar InBody 720). ,Fat-free mass, and skeletal muscle mass will be calculated. | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention. | |
Secondary | Change in body composition - Fat-free mass | Bioimpedance (Octopolar InBody 720). | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention] | |
Secondary | Change in body composition - Skeletal muscle mass | muscle mass Bioimpedance (Octopolar InBody 720). | Change from baseline at 8 weeks of intervention and at 16 weeks post intervention] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|